INOVIE GROUP

Name

INOVIE GROUP

Legal name

INOVIE Group SAS

Website

https://inovie.fr

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

akta.pro secondary industries

Laboratory Quality Systems, Accreditation & Proficiency Testing Programs (HLAJAIAM), Laboratory Informatics & Reporting (LIMS/ELR) Public Health Networks (HLAJAIAN), Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity) (HLAHAAAO)

Keywords

• Medical diagnostics services
• Clinical laboratory testing
• Medical biology analysis
• Pathology diagnostics
• Anatomopathology testing

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices20 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Laboratory Medical Biology Services: Revenue generated from performing medical biology analyses billed to social security and health insurance systems. Services include routine blood tests, specialized analyses, genetic testing, and pathology examinations. National Health Insurance (Assurance Maladie) and supplementary health insurers reimburse patients for covered analyses.
2. Patient Direct Services: Direct patient services including STI screening, without prescription tests, and specialized diagnostics. Some services covered by national insurance, others may have supplemental insurance coverage or minor patient contributions.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

INOVIE GROUP operates a France-wide network of more than 557 medical biology proximity laboratories and 65 high-performance technical platforms, providing diagnostic testing services including routine blood analyses, genetics, anatomopathology, STI screening, COVID-19 testing, and fertility diagnostics to individual patients, healthcare professionals, and partner healthcare institutions. The company also delivers digital result access through its INOVIE +me unified patient portal and deploys the Dedalus InVitro laboratory information management suite across its subsidiaries.

Product overview

INOVIE GROUP operates a platform-plus-modules architecture centered on a France-wide network of medical biology diagnostic laboratories. The core offering is the network of over 557 proximity laboratory sites and 65 high-performance technical platforms organized across 25 regional subsidiary brands. The unified patient-facing layer is the INOVIE +me digital platform, which provides a single portal for result access and lab management across all subsidiaries. Supporting modules include dedicated IST screening services (sans ordonnance, covering HIV, hepatitis B, syphilis, chlamydia, gonorrhea), COVID-19 testing, and INOVIE Fertility reproductive health services. The group also deploys the Dedalus InVitro Suite in SaaS mode for laboratory information management across medical biology, genetics, and anatomopathology. The subsidiary lab brands (INOVIE Labosud, INOVIE Biopyrénées, INOVIE CBM, INOVIE GEN-BIO, INOVIE BioMedilab, INOVIE Biofutur, INOVIE Bio-clinic, INOVIE Bioaxiome, INOVIE Axbio, INOVIE BIOLYSS, INOVIE Biopôle Antilles, INOVIE Labosud Provence, INOVIE Nealab, INOVIE Ocealab, INOVIE ProLAB, INOVIE RéuniLAB, INOVIE SynAIRBIO, and INOVIE Guevalt) represent regional sub-brands of the same laboratory service, consolidated under the INOVIE umbrella following multiple acquisitions.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Biology Diagnostic Laboratory Network
• INOVIE +me Patient Portal
• IST Screening Services (sans ordonnance)
• COVID-19 Testing Services
• INOVIE Fertility (INOVIE Fertilité)
• Chronic Kidney Disease (CKD) Screening
• Pertussis (Coqueluche) PCR Testing
• Dedalus InVitro Laboratory Suite

Quantifiable outcome

• 557 laboratory sites and 65 technical platforms serving patients across France
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and major.

• DedaluscoreTechnology or Integration · 6 February 2025Five-year strategic partnership for large-scale deployment of Dedalus InVitro suite in SaaS mode. INOVIE laboratories will gain access to comprehensive platform covering medical biology, genetics, and anatomopathology, including result servers, quality management tools, administrative and billing functions, and decision-support tools. Both parties describe this as a key step in INOVIE's digital transformation aimed at improving performance for patients and healthcare professionals.
• BiofuturmajorStrategic or Co-development Partner · 8 December 2021INOVIE is in the process of acquiring Biofutur, which operates approximately 60 laboratory sites in Île-de-France and generates annual revenue of 90 million euros. This acquisition would significantly expand INOVIE's presence in the Greater Paris region.

Scale indicators4 records

Recent moves13 records

Expansion highlights6 records

Broad incumbents

• Eurofins Scientific: Global leader in bioanalytical testing with significant clinical diagnostics and genomic services alongside its broader food/environment/pharma testing portfolio. Comparable to INOVIE in clinical and specialty diagnostics scale but much broader in scope.
• Mayo Clinic Laboratories: Reference laboratory arm of Mayo Clinic offering highly specialized and esoteric testing globally. Comparable to INOVIE in specialized diagnostics and genetics, though more focused on reference/rare-disease testing rather than walk-in routine biology.
• Sonic Healthcare: Australia-headquartered global medical diagnostics provider with extensive laboratory networks in Europe (including Germany, UK, Switzerland, Belgium). Comparable as a large multi-country clinical laboratory operator with similar scale economics and service mix.
• Quest Diagnostics: US-based leading clinical laboratory services company with broad routine and specialty testing menus. Comparable to INOVIE in clinical biology operations, patient-direct services, and digital result delivery platforms, though at significantly larger scale and concentrated in North America.
• Labcorp (Laboratory Corporation of America): One of the world's largest clinical laboratory networks, offering routine and esoteric diagnostics across the US and internationally. Comparable to INOVIE in routine and specialty biology services, lab consolidation strategy, and prescriber-facing digital tools, though operating at much greater scale.

Direct peers

• Biogroup: Leading French private medical biology laboratory network with hundreds of sites across France. Directly competes with INOVIE in routine biology, screening services, and the same reimbursement/regulatory framework, pursuing a similar regional-rollup strategy.
• Cerba HealthCare: French-headquartered specialty and routine clinical laboratory group with strong presence in France, Belgium, and Luxembourg. Closely comparable to INOVIE in terms of French market positioning, routine and specialty biology services, and hospital/clinic partnerships.
• Synlab: Europe's largest medical diagnostics services provider, operating clinical laboratory networks across multiple countries. Directly comparable to INOVIE as a pan-European rollup of regional medical biology laboratories serving both patients and prescribers.
• Unilabs: Major European clinical laboratory network operating across 15+ countries with routine and specialty testing services. Comparable to INOVIE as a multi-country rollup focused on medical biology, with significant operations in France via Unilabs France.

Regional players

• Medipath: French pathology and anatomic pathology laboratory network. Comparable to INOVIE's anatomopathology line of business and operates in the same French regulatory and reimbursement environment, though narrower in scope (focused on pathology).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/groupe-inovie

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries22 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INOVIE GROUP